CD38 and Miyoshi myopathy: It has been shown that among several validated MM targets such as SLAMF and CD38, only BCMA expression is upregulated in MM progression (23–25), a feature that satisfies a key criterion in CAR T-cell design, suggesting that BCMA is one of the most promising targets for the treatment of MM with CAR-T.